- IGFBP3 binds insulin growth factors 1 and 2 (IGF-1, IGF-2) and acts as the main carrier of both factors through the bloodstream [R].
- Higher levels of IGFBP-3 in the body (T) [R]
- Decreased levels of IGFBP-3 in the body (G) [R]
The Minor "G" allele is associated with:
- Premenopausal breast cancer (BCA) in subjects using oral contraception [R].
- Prostate cancer [R].
- Esophageal squamous cell carcinoma (ESCC) [R].
- Increased risk of developing Breast cancer [R].
- Larger tumors in subjects for the cancers listed above [R] [R].
- Tumors that respond poorly to chemoradiotherapy [R].
- A decrease in ASMI in elderly subjects with this polymorphism [R]. ASMI leads to increased muscle and bone disabilities [R].
- Less favorable outcome to treatment with recombinant growth hormone in subjects with Turner syndrome [R].
- Gastric carcinoma if the polymorphism is paired with a polymorphism in the IGF2 gene [R].
- Decreased risk of Bladder cancer and colorectal cancer [R] [R].
- Renal cell carcinoma [R]
- Increased levels of LDL cholesterol in the body, which in turn increases risk of obesity [R].
The Major "T" allele is associated with:
- Decreased risk of developing breast cancer, prostate, ESCC, breast, and renal forms of cancer [R] [R] [R] [R] [R].
- Increased survival rate after developing these cancers with proper treatment [R] [R] [R].
- Reduced risk of developing muscle or bone disabilities during aging [R].
- Possible increased risk of developing bladder cancer and colorectal cancer [R] [R].
- Reduced LDL cholesterol levels in the body, which could reduce risks of obesity [R].